Australia's most trusted
source of pharma news
Wednesday, 05 February 2025
Posted 3 February 2025 AM
Eli Lilly's Retevmo stole the limelight over the weekend as Health Minister Mark Butler took to mainstream media to announce that the targeted lung cancer treatment is now subsidised by the government.
Retevmo was the sole new addition to the PBS for February and marks the first-ever RET-altered cancer drug to be listed on the scheme. While Roche previously marketed Gavreto, which belongs to the same drug class, the drug was pulled from the Australian market last year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.